Autolus Therapeutics PLC (NAS:AUTL)
$ 3.92 0.05 (1.29%) Market Cap: 1.04 Bil Enterprise Value: 335.67 Mil PE Ratio: 0 PB Ratio: 1.79 GF Score: 55/100

Autolus Therapeutics PLC To Discuss Four Clinical Data Updates at the European Hematology Association Congress Call Transcript

Jun 13, 2022 / 11:30AM GMT
Release Date Price: $2.28 (-10.94%)
Operator

Good day, and welcome to the Autolus Therapeutics EHA Investor Call. (Operator Instructions) As a reminder, this call is being recorded. I would now like to turn the call over to CEO, Christian Itin. You may begin.

Christian Martin Itin
Autolus Therapeutics plc - CEO & Director

Thank you, Michelle, and good morning or good afternoon, everyone, and thank you for joining us to take part in today's call to discuss the data presented at the European Hematology Association Congress that has recently been held in Vienna.

Joining us today, we're extremely pleased to welcome Dr. Steven Horwitz from the Department of Medicine, Lymphoma Service at Memorial Sloan Kettering Cancer Center and a Professor of Medicine at Weill Cornell Medical College, Cornell University; and Dr. Kate Cwynarski, Chair of the U.K. T cell Lymphoma Group and Consultant Hematologist, University College London Hospital; Dr. Martin Pule, our Chief Scientific Officer; and Dr. Edgar Braendle, our Chief Development Officer, will also participate in this call.

Before we begin, I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot